Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2635-2644

  Lee, Chun Geun ^a   Herzog, Erica L ^a   Ahangari, Farida ^a   Zhou, Yang ^a   Gulati, Mridu ^a   Lee, Chang Min ^a   Peng, Xueyan ^a   Feghali Bostwick, Carol ^b,c   Jimenez, Sergio A ^d   Varga, John ^e   Elias, Jack A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CHITINASE 1; CHITOTRIOSIDASE; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCULATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; LUNG; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SCLERODERMA; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; HEXOSAMINIDASES; HUMANS; LUNG DISEASES, INTERSTITIAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NIH 3T3 CELLS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865411180     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201115     Document Type: Article

References (61)

1. Steen, V. D., and T. A. Medsger. 2007. Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66: 940-944.
2. Harrison, N. K., A. R. Myers, B. Corrin, G. Soosay, A. Dewar, C. M. Black, R. M. Du Bois, and M. Turner-Warwick. 1991. Structural features of interstitial lung disease in systemic sclerosis. Am. Rev. Respir. Dis. 144: 706-713.
3. Benan, M., I. Hande, and O. Gul. 2007. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin. Rheumatol. 26: 349-354.
4. Mouthon, L., A. Bérezné, L. Guillevin, and D. Valeyre. 2010. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir. Med. 104 (Suppl. 1): S59-S69.
5. 1 in nonspecific insterstitial pneumonities compared with usual interstitial pneumonitis. Chest 120: S70-S71.
6. Liu, Y. 2006. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69: 213-217.
7. Martin, M., J. Lefaix, and S. Delanian. 2000. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int. J. Radiat. Oncol. Biol. Phys. 47: 277-290.
8. Sargent, J. L., A. Milano, S. Bhattacharyya, J. Varga, M. K. Connolly, H. Y. Chang, and M. L. Whitfield. 2010. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J. Invest. Dermatol. 130: 694-705.
9. Ihn, H., K. Yamane, M. Kubo, and K. Tamaki. 2001. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum. 44: 474-480.
10. Needleman, B. W., J. Choi, A. Burrows-Mezu, and J. A. Fontana. 1990. Secretion and binding of transforming growth factor beta by scleroderma and normal dermal fibroblasts. Arthritis Rheum. 33: 650-656.
11. Kubo, M., H. Ihn, K. Yamane, and K. Tamaki. 2002. Upregulated expression of transforming growth factor-β receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J. Rheumatol. 29: 2558-2564.
12. Yamane, K., H. Ihn, M. Kubo, and K. Tamaki. 2002. Increased transcriptional activities of transforming growth factor β receptors in scleroderma fibroblasts. Arthritis Rheum. 46: 2421-2428.
13. Kawakami, T., H. Ihn, W. Xu, E. Smith, C. LeRoy, and M. Trojanowska. 1998. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J. Invest. Dermatol. 110: 47-51.
14. Samuel, G. H., A. M. Bujor, S. S. Nakerakanti, F. N. Hant, and M. Trojanowska. 2010. Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 3: 25.
15. Asano, Y., H. Ihn, K. Yamane, M. Kubo, and K. Tamaki. 2004. Impaired Smad7- Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J. Clin. Invest. 113: 253-264.
16. Lee, C. G., C. A. Da Silva, C. S. Dela Cruz, F. Ahangari, B. Ma, M. J. Kang, C. H. He, S. Takyar, and J. A. Elias. 2011. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 73: 479-501.
17. Kzhyshkowska, J., A. Gratchev, and S. Goerdt. 2007. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2: 128-146.
18. Renkema, G. H., R. G. Boot, A. Strijland, W. E. Donker-Koopman, M. van den Berg, A. O. Muijsers, and J. M. Aerts. 1997. Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur. J. Biochem. 244: 279-285.
19. Bargagli, E., M. Margollicci, N. Nikiforakis, A. Luddi, A. Perrone, S. Grosso, and P. Rottoli. 2007. Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration 74: 548-552.
20. Malaguarnera, L. 2006. Chitotriosidase: the yin and yang. Cell. Mol. Life Sci. 63: 3018-3029.
21. Pesce, J., M. Kaviratne, T. R. Ramalingam, R. W. Thompson, J. F. Urban, Jr., A. W. Cheever, D. A. Young, M. Collins, M. J. Grusby, and T. A. Wynn. 2006. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116: 2044-2055.
22. Migliaccio, C. T., M. C. Buford, F. Jessop, and A. Holian. 2008. The IL-4Rα pathway in macrophages and its potential role in silica-induced pulmonary fibrosis. J. Leukoc. Biol. 83: 630-639.
23. Gan, Y., R. Reilkoff, S. Peng, T. Russell, Q. Chen, S. K. Mathai, R. Homer, M. Gulati, J. Siner, J. Elias, et al. 2011. Role of semaphorin 7a in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum. 63: 2484-2494.
24. Mathai, S. K., M. Gulati, X. Peng, T. R. Russell, A. C. Shaw, A. N. Rubinowitz, L. A. Murray, J. M. Siner, D. E. Antin-Ozerkis, R. R. Montgomery, et al. 2010. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90: 812-823.
25. Abignano, G., M. Buch, P. Emery, and F. Del Galdo. 2011. Biomarkers in the management of scleroderma: an update. Curr. Rheumatol. Rep. 13: 4-12.
26. Murray, L. A., R. Rosada, A. P. Moreira, A. Joshi, M. S. Kramer, D. P. Hesson, R. L. Argentieri, S. Mathai, M. Gulati, E. L. Herzog, and C. M. Hogaboam. 2010. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 5: e9683.
27. Hollak, C. E., S. van Weely, M. H. van Oers, and J. M. Aerts. 1994. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J. Clin. Invest. 93: 1288-1292.
28. Lee, C. G., D. Hartl, G. R. Lee, B. Koller, H. Matsuura, C. A. Da Silva, M. H. Sohn, L. Cohn, R. J. Homer, A. A. Kozhich, et al. 2009. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J. Exp. Med. 206: 1149-1166.
29. Bhandari, V., R. Choo-Wing, C. G. Lee, Z. Zhu, J. H. Nedrelow, G. L. Chupp, X. Zhang, M. A. Matthay, L. B. Ware, R. J. Homer, et al. 2006. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat. Med. 12: 1286-1293.
30. Zhu, Z., T. Zheng, R. J. Homer, Y. K. Kim, N. Y. Chen, L. Cohn, Q. Hamid, and J. A. Elias. 2004. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304: 1678-1682.
31. Zhou, Y., D. J. Schneider, E. Morschl, L. Song, M. Pedroza, H. Karmouty- Quintana, T. Le, C. X. Sun, and M. R. Blackburn. 2011. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186: 1097-1106.
32. Zhu, Z., R. J. Homer, Z. Wang, Q. Chen, G. P. Geba, J. Wang, Y. Zhang, and J. A. Elias. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103: 779-788.
33. Lee, C. G., S. J. Cho, M. J. Kang, S. P. Chapoval, P. J. Lee, P. W. Noble, T. Yehualaeshet, B. Lu, R. A. Flavell, J. Milbrandt, et al. 2004. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis. J. Exp. Med. 200: 377-389.
34. Asano, Y., H. Ihn, M. Jinnin, K. Tamaki, and S. Sato. 2011. Altered dynamics of transforming growth factor β (TGF-β) receptors in scleroderma fibroblasts. Ann. Rheum. Dis. 70: 384-387.
35. Zhao, W., G. Gomez, S. H. Yu, J. J. Ryan, and L. B. Schwartz. 2008. TGF-β1 attenuates mediator release and de novo Kit expression by human skin mast cells through a Smad-dependent pathway. J. Immunol. 181: 7263-7272.
36. Lee, P. J., X. Zhang, P. Shan, B. Ma, C. G. Lee, R. J. Homer, Z. Zhu, M. Rincon, B. T. Mossman, and J. A. Elias. 2006. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J. Clin. Invest. 116: 163-173.
37. Létuvé, S., A. Kozhich, A. Humbles, Y. Brewah, M. C. Dombret, M. Grandsaigne, H. Adle, R. Kolbeck, M. Aubier, A. J. Coyle, and M. Pretolani. 2010. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am. J. Pathol. 176: 638-649.
38. Guo, Y., W. He, A. M. Boer, R. A. Wevers, A. M. de Bruijn, J. E. Groener, C. E. Hollak, J. M. Aerts, H. Galjaard, and O. P. van Diggelen. 1995. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J. Inherit. Metab. Dis. 18: 717-722.
39. Fang, F., K. Ooka, S. Bhattacharyya, J. Wei, M. Wu, P. Du, S. Lin, F. Del Galdo, C. A. Feghali-Bostwick, and J. Varga. 2011. The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am. J. Pathol. 178: 2077-2090.
40. Li, M., M. S. Krishnaveni, C. Li, B. Zhou, Y. Xing, A. Banfalvi, A. Li, V. Lombardi, O. Akbari, Z. Borok, and P. Minoo. 2011. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J. Clin. Invest. 121: 277-287.
41. Lee, C. G., R. J. Homer, Z. Zhu, S. Lanone, X. Wang, V. Koteliansky, J. M. Shipley, P. Gotwals, P. Noble, Q. Chen, et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J. Exp. Med. 194: 809-821.
42. Kubo, M., H. Ihn, K. Yamane, and K. Tamaki. 2001. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 44: 731-734.
43. Siegert, A., E. Ritz, S. Orth, and J. Wagner. 1999. Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-β1 in vascular smooth muscle. J. Mol. Med. 77: 437-445.
44. Bargagli, E., M. Margollicci, A. Luddi, N. Nikiforakis, M. G. Perari, S. Grosso, A. Perrone, and P. Rottoli. 2007. Chitotriosidase activity in patients with interstitial lung diseases. Respir. Med. 101: 2176-2181.
45. Seibold, M. A., S. Donnelly, M. Solon, A. Innes, P. G. Woodruff, R. G. Boot, E. G. Burchard, and J. V. Fahy. 2008. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. J. Allergy Clin. Immunol. 122: 944-950.e43.
46. Ioannidis, J. P., P. G. Vlachoyiannopoulos, A. B. Haidich, T. A. Medsger, Jr., M. Lucas, C. J. Michet, M. Kuwana, H. Yasuoka, F. van den Hoogen, L. Te Boome, et al. 2005. Mortality in systemic sclerosis: an international metaanalysis of individual patient data. Am. J. Med. 118: 2-10.
47. Goh, N. S., S. R. Desai, S. Veeraraghavan, D. M. Hansell, S. J. Copley, T. M. Maher, T. J. Corte, C. R. Sander, J. Ratoff, A. Devaraj, et al. 2008. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 177: 1248-1254.
48. Hant, F. N., and R. M. Silver. 2011. Biomarkers of scleroderma lung disease: recent progress. Curr. Rheumatol. Rep. 13: 44-50.
49. Varga, J., and B. Pasche. 2008. Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr. Opin. Rheumatol. 20: 720-728.
50. Leask, A. 2010. Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 106: 1675-1680.
51. Querfeld, C., B. Eckes, C. Huerkamp, T. Krieg, and S. Sollberg. 1999. Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma. J. Dermatol. Sci. 21: 13-22.
52. Leask, A. 2008. Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell. Signal. 20: 1409-1414.
53. Varga, J., and B. Pasche. 2009. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5: 200-206.
54. Radstake, T. R., O. Gorlova, B. Rueda, J. E. Martin, B. Z. Alizadeh, R. Palomino-Morales, M. J. Coenen, M. C. Vonk, A. E. Voskuyl, A. J. Schuerwegh, et al; Spanish Scleroderma Group. 2010. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 42: 426-429.
55. Ihn, H. 2008. Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J. Dermatol. Sci. 49: 103-113.
56. Wynn, T. A. 2004. Fibrotic disease and the TH1/TH2 paradigm. Nat. Rev. Immunol. 4: 583-594.
57. Hasegawa, M., S. Sato, T. Nagaoka, M. Fujimoto, and K. Takehara. 2003. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology (Basel) 207: 141-147.
58. Romano, C., A. Sellitto, U. De Fanis, R. Rossiello, L. Rossiello, R. Giunta, and G. Lucivero. 2009. A scleroderma-like cutaneous syndrome associated with a marked Th2-type immune response occurring after a prosthetic joint implant. J. Clin. Rheumatol. 15: 133-137.
59. Granel, B., C. Chevillard, Y. Allanore, V. Arnaud, S. Cabantous, S. Marquet, P. J. Weiller, J. M. Durand, J. R. Harlé, C. Grange, et al. 2006. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 58: 693-699.
60. Matsushita, M., T. Yamamoto, and K. Nishioka. 2004. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int. Arch. Allergy Immunol. 135: 348-356.
61. Rankin, A. L., J. B. Mumm, E. Murphy, S. Turner, N. Yu, T. K. McClanahan, P. A. Bourne, R. H. Pierce, R. Kastelein, and S. Pflanz. 2010. IL-33 induces IL- 13-dependent cutaneous fibrosis. J. Immunol. 184: 1526-1535.